Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piro Lito

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Nature|May 31, 2023
Pan-KRAS inhibitor disables oncogenic signalling and tumour growthDongsung Kim, Lorenz Herdeis, Dorothea Rudolph, et al.
Nature Medicine|July 18, 2017
An approach to suppress the evolution of resistance in BRAF<sup>V600E</sup>-mutant cancerYaohua Xue, Luciano Martelotto, Timour Baslan, et al.
Science Translational Medicine|May 30, 2014
Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemiaStephen S Chung, Eunhee Kim, Jae H Park, et al.
The Oncologist|August 17, 2023
Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung CancerArielle Elkrief, Biagio Riccuiti, Joao V Alessi, et al.
British Journal of Cancer|December 29, 2021
Immune biomarkers and response to checkpoint inhibition of BRAF<sup>V600</sup> and BRAF non-V600 altered lung cancersYonina R Murciano-Goroff, Terry Pak, Sebastian Mondaca, et al.
Cell|May 7, 2026
Disrupted molecular glue complex drives RAS inhibitor resistanceBen Sang, Ling Feng Ye, Zheng Fu, et al.
Nature|October 31, 2024
RAS-mutant leukaemia stem cells drive clinical resistance to venetoclaxJunya Sango, Saul Carcamo, Maria Sirenko, et al.
Cell Reports. Medicine|August 2, 2024
In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAF<sup>V600E</sup> lung adenocarcinomaMarie-Julie Nokin, Elodie Darbo, Elodie Richard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2021
<i>KRAS</i> <sup>G12C</sup> Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung AdenocarcinomaGregory D Jones, Raul Caso, Kay See Tan, et al.
Cell Reports. Medicine|October 16, 2024
Modeling lung adenocarcinoma metastases using patient-derived organoidsYuan Liu, Manendra Lankadasari, Joel Rosiene, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Nature|May 31, 2023
Pan-KRAS inhibitor disables oncogenic signalling and tumour growthDongsung Kim, Lorenz Herdeis, Dorothea Rudolph, et al.
Nature Medicine|July 18, 2017
An approach to suppress the evolution of resistance in BRAF<sup>V600E</sup>-mutant cancerYaohua Xue, Luciano Martelotto, Timour Baslan, et al.
Science Translational Medicine|May 30, 2014
Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemiaStephen S Chung, Eunhee Kim, Jae H Park, et al.
The Oncologist|August 17, 2023
Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung CancerArielle Elkrief, Biagio Riccuiti, Joao V Alessi, et al.
British Journal of Cancer|December 29, 2021
Immune biomarkers and response to checkpoint inhibition of BRAF<sup>V600</sup> and BRAF non-V600 altered lung cancersYonina R Murciano-Goroff, Terry Pak, Sebastian Mondaca, et al.
Cell|May 7, 2026
Disrupted molecular glue complex drives RAS inhibitor resistanceBen Sang, Ling Feng Ye, Zheng Fu, et al.
Nature|October 31, 2024
RAS-mutant leukaemia stem cells drive clinical resistance to venetoclaxJunya Sango, Saul Carcamo, Maria Sirenko, et al.
Cell Reports. Medicine|August 2, 2024
In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAF<sup>V600E</sup> lung adenocarcinomaMarie-Julie Nokin, Elodie Darbo, Elodie Richard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2021
<i>KRAS</i> <sup>G12C</sup> Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung AdenocarcinomaGregory D Jones, Raul Caso, Kay See Tan, et al.
Cell Reports. Medicine|October 16, 2024
Modeling lung adenocarcinoma metastases using patient-derived organoidsYuan Liu, Manendra Lankadasari, Joel Rosiene, et al.
Pageof 5